5α-hydroxy-6β-N-{3-[4-(3-aminopropylamino)butylamino]-propylamino}cholestan-3β-ol | 1191043-98-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 5α-hydroxy-6β-N-{3-[4-(3-aminopropylamino)butylamino]-propylamino}cholestan-3β-ol
• 英文别名: 5α-hydroxy-6β-{3-[4-(3-aminopropylamino)butylamino]propylamino}cholestan-3β-ol；(3S,5R,6R,8S,9S,10R,13R,14S,17R)-6-[3-[4-(3-aminopropylamino)butylamino]propylamino]-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,5-diol
• CAS: 1191043-98-7
• 化学式: C₃₇H₇₂N₄O₂
• 分子量: 605.004
• InChiKey: DYROMGAQKQJPBK-DSDLKRJVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  43
• 可旋转键数：
  18
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  103
• 氢给体数：
  6
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  精胺 、 胆固醇-5Alpha,6Alpha-环氧化物 在 lithium perchlorate 作用下， 以 乙醇 为溶剂， 反应 96.0h， 生成 5α-hydroxy-6β-N-{3-[4-(3-aminopropylamino)butylamino]-propylamino}cholestan-3β-ol
  参考文献：
  名称：

  Synthesis of New Alkylaminooxysterols with Potent Cell Differentiating Activities: Identification of Leads for the Treatment of Cancer and Neurodegenerative Diseases

  摘要：

  We describe here the syntheses and the biological properties of new alkylaminooxysterols. Compounds were synthesized through the trans-diaxial aminolysis of 5,6-alpha-epoxysterols with various natural amines including histamine, putrescine, spermidine, or spermine. The regioselective synthesis of these 16 new 5 alpha-hydroxyl-6 beta-aminoalkylsterols is presented. Compounds were first screened for dendrite outgrowth and cytotoxicity in vitro, and two leads were selected and further characterized. 5 alpha-Hydroxy-6 beta-[2-(1-H-imidazol-4-yl)ethylamino]cholestan -3 beta-ol, called dendrogenin A, induced growth control, differentiation, and the death of tumor cell lines representative of various cancers including metastatic melanoma and breast cancer. 5 alpha-hydroxyl-6 beta-[3-(4-aminobutylamino)propylamino]cholest-7-en-3 beta-ol, called dendrogenin B, induced neurite outgrowth on various cell lines, neuronal differentiation in pluripotent cells, and survival of normal neurones at nanomolar concentrations. In summary, we report that two new alkylaminooxysterols, dendrogenin A and dendrogenin B, are the first members of a class of compounds that induce cell differentiation at nanomolar concentrations and represent promising new leads for the treatment of cancer or neurodegenerative diseases.

  DOI：

  10.1021/jm901063e

文献信息

• PROCESS FOR THE PREPARATION OF STEROL DERIVATIVES
  申请人：INSERM (Institut National de la Sante et de la Recherche Medicale)

  公开号：US20140309417A1

  公开（公告）日：2014-10-16

  The present invention relates to a process for the preparation of sterol derivatives comprising the reaction of an α-epoxy compound with an amine in an alcohol comprising 3 to 5 carbon atoms as a solvent.

  本发明涉及一种制备甾醇衍生物的方法，包括在一种含有3至5个碳原子的醇作为溶剂的情况下，将α-环氧化合物与胺反应。
• METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS
  申请人：The Rockefeller University

  公开号：EP3402477A2

  公开（公告）日：2018-11-21
• TREATMENT AND DIAGNOSIS OF CANCER
  申请人：Rgenix, Inc.

  公开号：US20190125745A1

  公开（公告）日：2019-05-02

  This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors for the treatment of cancer.
• US9447141B2
  申请人：——

  公开号：US9447141B2

  公开（公告）日：2016-09-20
• [EN] METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS<br/>[FR] MÉTHODES POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À DES CELLULES SUPPRESSIVES DÉRIVÉES DE CELLULES MYÉLOÏDES
  申请人：UNIV ROCKEFELLER

  公开号：WO2017123568A2

  公开（公告）日：2017-07-20

  The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXRβ agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.